Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are investigating the long-term safety and effectiveness of a combined drug treatment using xanomeline tartratetrospium chloride in an immediate release capsule KarXT and xanomeline enteric capsules KarX-EC for people with agitation linked to Alzheimers Disease. This study is an open-label extension of earlier studies CN012-0023 and CN012-0024. It aims to understand how well these treatments work over time and monitor any side effects. Participants who completed the previous studies will receive specified doses of KarXT and KarX-EC according to a set schedule. This phase 3 study does not include a comparison group and all participants receive the combined treatment. The treatment period lasts approximately 30 weeks, during which the effects and safety of these medications will be observed. During the study, participants will be closely monitored for any adverse events, changes in cognitive function, movement disorders, vital signs, and other health measures. Assessments include scales like the Mini-Mental State Examination MMSE, Abnormal Involuntary Movement Scale AIMS, and others related to agitation and side effects. Safety checks such as lab tests, ECGs, and questionnaires will be regularly conducted. The total study duration for participants is about 30 weeks, with follow-up to evaluate overall treatment tolerability and impact.
Actively Recruiting
Researchers are studying the effects and safety of SPN-812 viloxazine extended release in children aged 4 to 5 years who have Attention-DeficitHyperactivity Disorder ADHD. This study is a Phase 4, randomized, double-blind, placebo-controlled trial designed to compare SPN-812 with a placebo in preschool-age children diagnosed with ADHD. The goal is to evaluate how well the medication works and how tolerable it is in this young population. Participants will be randomly assigned to receive either 100mg SPN-812 or a placebo once daily for a 6-week treatment period. Before starting treatment, children will be screened for up to 4 weeks to determine eligibility. The total study duration for each participant is up to 10 weeks, including screening and treatment. This design allows researchers to compare the effects of SPN-812 against placebo over a set timeframe. During the study, participants will be evaluated using the ADHD Rating Scale, 4th Edition, Preschool Version ADHD-RS-IV-P to measure changes in ADHD symptoms. Other assessments include the Clinical Global Impression of Severity and Change scores. Parents or guardians will provide consent, and children will be regularly monitored for safety and treatment response. Researchers will collect data at baseline and at the end of the 6-week treatment period to assess the medications impact and any side effects.
Actively Recruiting
Healthy Volunteer
This research evaluates the growth and tolerance of infants consuming a new extensively hydrolyzed cow milk protein formula compared to a currently marketed extensively hydrolyzed cow milk protein formula. The study focuses on healthy, term infants aged approximately 10 to 14 days at enrollment, aiming to show that the investigational formula supports typical growth and is well tolerated. Secondary goals include examining feeding tolerance, stool characteristics, intake amounts, and any health issues arising during the study. Participants will be randomly assigned to receive either the investigational extensively hydrolyzed casein formula made with a new manufacturing process or a commercially available extensively hydrolyzed casein formula. Both formulas have the same nutritional content per 100 kcal. The study formula feeding will continue through approximately 126 days of age. During the study, infants growth measurements such as weight gain, body length, and head circumference will be tracked up to 131 days of age. Researchers will also monitor stool characteristics, formula intake, tolerance signs like spit-up or fussiness, and any medically confirmed adverse events. Caregivers will be supported with remote visits and assessments, including the use of reliable internet for study participation.